Volume 13, Issue 11, Pages (November 2012)

Slides:

Advertisements

Similar presentations

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Advertisements

Fever of unknown origin and cancer: a population-based study

Volume 14, Issue 4, Pages (April 2013)

Volume 16, Issue 8, Pages (August 2015)

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Volume 16, Issue 2, Pages (February 2015)

Volume 18, Issue 6, Pages (June 2017)

Volume 376, Issue 9747, Pages (October 2010)

Volume 16, Issue 9, Pages (September 2015)

Volume 15, Issue 6, Pages (May 2014)

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

Volume 14, Issue 4, Pages (April 2013)

Volume 377, Issue 9783, Pages (June 2011)

Volume 373, Issue 9666, Pages (March 2009)

Volume 371, Issue 9611, Pages (February 2008)

Volume 9, Issue 5, Pages (May 2008)

Volume 14, Issue 3, Pages (March 2013)

Volume 15, Issue 4, Pages (April 2014)

Volume 15, Issue 4, Pages (April 2014)

Volume 373, Issue 9663, Pages (February 2009)

Volume 14, Issue 7, Pages (June 2013)

Volume 15, Issue 4, Pages (April 2014)

Volume 9, Issue 10, Pages (October 2008)

Volume 14, Issue 8, Pages (July 2013)

Volume 14, Issue 8, Pages (July 2013)

Volume 12, Issue 7, Pages (July 2011)

Volume 15, Issue 6, Pages (May 2014)

Volume 18, Issue 3, Pages (March 2017)

Volume 379, Issue 9812, Pages (January 2012)

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Volume 15, Issue 1, Pages (January 2014)

Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label,

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild- type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

Volume 387, Issue 10023, Pages (March 2016)

Volume 14, Issue 6, Pages (May 2013)

Volume 11, Issue 4, Pages (April 2010)

Volume 373, Issue 9666, Pages (March 2009)

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Volume 385, Issue 9962, Pages (January 2015)

Volume 17, Issue 8, Pages (August 2016)

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled,

Volume 19, Issue 4, Pages (April 2018)

Volume 15, Issue 8, Pages (July 2014)

Volume 371, Issue 9625, Pages (May 2008)

Volume 373, Issue 9676, Pages (May 2009)

Volume 18, Issue 8, Pages (August 2017)

Volume 16, Issue 15, Pages (November 2015)

Volume 388, Issue 10055, Pages (October 2016)

Volume 15, Issue 6, Pages (May 2014)

Volume 381, Issue 9880, Pages (May 2013)

Volume 14, Issue 6, Pages (May 2013)

Volume 16, Issue 15, Pages (November 2015)

Volume 5, Issue 4, Pages (April 2018)

Volume 14, Issue 8, Pages (July 2013)

Volume 15, Issue 6, Pages (May 2014)

Volume 15, Issue 1, Pages (January 2014)

Volume 15, Issue 8, Pages (July 2014)

Volume 11, Issue 1, Pages (January 2010)

A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43– 9006) in Previously Treated Non–Small-Cell Lung Cancer Patients: Eastern.

Volume 18, Issue 10, Pages (October 2017)

Volume 376, Issue 9747, Pages (October 2010)

DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Volume 20, Issue 5, Pages (May 2019)

Volume 14, Issue 7, Pages (June 2013)

Volume 371, Issue 9611, Pages (February 2008)

A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell.

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Volume 20, Issue 7, Pages (July 2019)

Presentation transcript:

Volume 13, Issue 11, Pages 1161-1170 (November 2012) First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial Prof Siow Ming Lee, MD, Iftekhar Khan, MSc, Sunil Upadhyay, MD, Conrad Lewanski, FRCP, Stephen Falk, MD, Geraldine Skailes, FRCR, Ernie Marshall, MD, Prof Penella J Woll, FRCP, Matthew Hatton, FRCR, Rohit Lal, MRCP, Richard Jones, FRCR, Elizabeth Toy, FRCR, David Chao, DPhil, Gary Middleton, MD, Sue Bulley, SRN, Yenting Ngai, BSc, Robin Rudd, MD, Prof Allan Hackshaw, MSc, Prof Chris Boshoff, MD The Lancet Oncology Volume 13, Issue 11, Pages 1161-1170 (November 2012) DOI: 10.1016/S1470-2045(12)70412-6 Copyright © 2012 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile *Patients with no recorded start date of study drug or dosing details. ECOG=Eastern Cooperative Oncology Group performance status. CRCL=creatinine clearance. The Lancet Oncology 2012 13, 1161-1170DOI: (10.1016/S1470-2045(12)70412-6) Copyright © 2012 Elsevier Ltd Terms and Conditions

Figure 2 Overall survival and progression-free survival for all patients HR=hazard ratio. The Lancet Oncology 2012 13, 1161-1170DOI: (10.1016/S1470-2045(12)70412-6) Copyright © 2012 Elsevier Ltd Terms and Conditions

Figure 3 Overall survival and progression-free survival according to whether patients on erlotinib developed first-cycle rash or not HR=hazard ratio. The Lancet Oncology 2012 13, 1161-1170DOI: (10.1016/S1470-2045(12)70412-6) Copyright © 2012 Elsevier Ltd Terms and Conditions